James William Rogers Sells 22,529 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 22,529 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,117,663.69. Following the completion of the transaction, the chief financial officer owned 132,337 shares in the company, valued at $6,565,238.57. This trade represents a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Wednesday, August 19th, James William Rogers sold 26,313 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Stock Performance

NASDAQ TEM opened at $72.69 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $13.12 billion, a P/E ratio of -50.48 and a beta of 3.58. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32. The firm has a 50-day moving average price of $52.93 and a two-hundred day moving average price of $51.36.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the firm earned ($0.22) earnings per share. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. Analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Guggenheim upped their target price on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Freedom Capital raised Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Needham & Company LLC restated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Finally, Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.69.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its stake in Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after purchasing an additional 162 shares during the last quarter. Truist Financial Corp lifted its holdings in Tempus AI by 5.8% during the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after buying an additional 194 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Tempus AI by 3.5% in the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock worth $377,000 after acquiring an additional 219 shares during the period. SeaCrest Wealth Management LLC lifted its position in shares of Tempus AI by 3.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock worth $524,000 after purchasing an additional 229 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Tempus AI by 29.4% in the fourth quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock valued at $65,000 after buying an additional 250 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.